أعرض في EDS

A Phase 1/2 Trial of the Insulin Growth Factor 1 Receptor (IGF-1R) inhibitor, Linsitinib in Combination with Bortezomib (BTZ) and Dexamethasone (Dex) for the Treatment of Relapsed/Refractory Multiple Myeloma (MM)

التفاصيل البيبلوغرافية
العنوان: A Phase 1/2 Trial of the Insulin Growth Factor 1 Receptor (IGF-1R) inhibitor, Linsitinib in Combination with Bortezomib (BTZ) and Dexamethasone (Dex) for the Treatment of Relapsed/Refractory Multiple Myeloma (MM)
المؤلفون: Andrzej Jakubowiak, Donna E. Reece, Darrell White, Zhihua Li, J. Kaufmann, Suzanne Trudel, Rodger E. Tiedemann, Vishal Kukreti, M Gyger, Christine Chen, E. Gul, Anca Prica, Richard Leblanc
المصدر: Clinical Lymphoma Myeloma and Leukemia. 15:e286-e287
بيانات النشر: Elsevier BV, 2015.
سنة النشر: 2015
مصطلحات موضوعية: Cancer Research, Linsitinib, business.industry, Bortezomib, Insulin, medicine.medical_treatment, Growth factor, Hematology, Pharmacology, medicine.disease, chemistry.chemical_compound, Oncology, chemistry, Relapsed refractory, Medicine, business, Receptor, Multiple myeloma, Dexamethasone, medicine.drug
تدمد: 2152-2650
DOI: 10.1016/j.clml.2015.07.588
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::6294c3bcf6549ec80e4a8e74e9fce4a2
https://doi.org/10.1016/j.clml.2015.07.588
Rights: CLOSED
رقم الانضمام: edsair.doi...........6294c3bcf6549ec80e4a8e74e9fce4a2
قاعدة البيانات: OpenAIRE
الوصف
تدمد:21522650
DOI:10.1016/j.clml.2015.07.588